cefixime and dicloxacillin tablets – Dual Antibiotic Power for Resistant Infections

Introduction

CEFEXOTIME DICLOXA is a broad-spectrum oral antibiotic formulation by Steris Healthcare, combining two potent agents—Cefixime and Extended-Release Dicloxacillin—to effectively combat a wide range of bacterial infections, especially those caused by β-lactamase-producing organisms. This dual-action therapy is particularly beneficial for resistant respiratory, skin, ENT, and urinary tract infections.

Scientific Composition

• Cefixime 200 mg: A third-generation cephalosporin with activity against Gram-negative organisms like E. coli, Klebsiella, and H. influenzae.

• Dicloxacillin ER 500 mg: A semi-synthetic penicillin, resistant to β-lactamases, effective against Gram-positive organisms such as Staphylococcus aureus, including penicillin-resistant strains.

Together, these agents ensure comprehensive antimicrobial coverage, targeting both common and resistant bacterial strains.

Mechanism of Action

• Cefixime inhibits bacterial cell wall synthesis by binding to PBPs, leading to cell lysis.

• Dicloxacillin binds to specific PBPs and resists β-lactamase degradation, making it effective against penicillin-resistant Staph infections.

This dual pharmacological approach helps prevent resistance, maximize therapeutic effect, and minimize relapse.

Clinical Use Cases and Target Infections

CEFEXOTIME DICLOXA is suitable for:

• Upper & lower respiratory tract infections: Pharyngitis, bronchitis, sinusitis, pneumonia

• Skin and soft tissue infections: Boils, abscesses, cellulitis

• ENT infections: Otitis media, tonsillitis

• Dental infections: Periodontitis, post-extraction infections

• Bone and joint infections

• Urinary tract infections (UTI)

• Post-operative infections

Ideal for polymicrobial or unclear infections, especially in outpatient settings where rapid relief is essential.

Therapeutic Advantages

• Broad-spectrum coverage in a single tablet

• Extended-release Dicloxacillin provides prolonged antibacterial action

• Minimizes dose frequency, enhancing patient compliance

• Particularly useful for mixed infections in dermatology, ENT, and respiratory medicine

• Offers a clinical edge where monotherapy may fail

Clinical Studies & Efficacy

• A comparative trial found that Cefixime + Dicloxacillin had a cure rate >90% in uncomplicated skin and soft tissue infections.

• In a study on community-acquired respiratory tract infections, this combination showed faster resolution of symptoms and lower recurrence rates.

• Proven to be effective against penicillinase-producing Staph and Gram-negative organisms, making it suitable for empirical treatment in clinics.

Pharmacokinetics

• Cefixime has a half-life of 3–4 hours, well-absorbed orally, and achieves therapeutic concentrations in respiratory secretions and urine.

• Dicloxacillin ER maintains bactericidal levels for up to 12 hours, reducing the need for multiple doses per day.

Dosage & Administration

• Recommended Dose: One tablet twice daily (every 12 hours) after meals or as directed by a healthcare professional.

• Duration: 5–10 days depending on infection severity.

• Special Considerations: Dose adjustment may be required in renal impairment.

Precautions

• Hypersensitivity to penicillins or cephalosporins

• Caution in patients with gastrointestinal diseases or renal dysfunction

• Monitor for C. difficile-associated diarrhea in prolonged use

• Not recommended for pediatric use unless specifically advised

Side Effects

Common: Nausea, flatulence, diarrhea, headache
Rare but Serious: Rash, eosinophilia, serum sickness, antibiotic-associated colitis

Prompt medical attention should be sought if severe allergic reactions occur.

Product Details

• Brand Name: CEFEXOTIME DICLOXA

• Packaging: 10 x 10 tablets (Alu-Alu blister)

• Storage: Store below 25°C, protect from moisture

• Shelf Life: 24 months from MFG date

• Marketed by: Steris Healthcare Pvt. Ltd.

Frequently Asked Questions (FAQs)

Q1. What makes this combination better than Cefixime alone?
The addition of Dicloxacillin ER covers penicillin-resistant Gram-positive bacteria, offering a more complete antibacterial spectrum.

Q2. Is this combination effective in diabetic foot infections?
Yes, it is useful in early-stage diabetic foot infections, especially where Staph aureus is involved.

Q3. Can it be used during pregnancy?
Only if prescribed by a doctor. Safety during pregnancy is not fully established.

Q4. How quickly does it show results?
Clinical improvement is often seen within 48 to 72 hours of initiating therapy.

Q5. Is it available for bulk and export supply?
Yes, Steris Healthcare supports bulk orders and third-party manufacturing.

Conclusion

CEFEXOTIME DICLOXA (Cefixime 200 mg + Dicloxacillin ER 500 mg) is a potent, dual-action antibiotic formulation that offers broad-spectrum coverage, enhanced patient compliance, and high clinical efficacy, especially in resistant or mixed bacterial infections. Backed by the trusted quality of Steris Healthcare, it is an ideal choice for physicians, hospitals, and PCD franchise partners looking to deliver reliable, result-driven treatment for challenging infections.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW